Axiodis CRO, the French subsidiary of the Oxurion Group, announces a dual AI-driven strategic initiative to transform clinical trials

This document constitutes regulated information in the sense of the Royal Decree of 14 November 2007 and/or the Law of 2 August 2002. For the full press release, download the PDF document(s) above.